Clinical Trials
12 trialsNCT04554914 2026-04-27
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Active not recruiting
NCT06277154 2025-07-24
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
Phase 2 Recruiting
NCT04996004 2024-12-11
TTI-621-03
Pfizer
Phase 2 Terminated
NCT03420014 2023-10-10
FIBROSARC US
Philogen S.p.A.
Phase 2 Unknown
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT00668148 2018-07-17
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Eli Lilly and Company
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT00297258 2016-02-03
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
GlaxoSmithKline
Phase 2 Completed
NCT00093080 2015-02-13
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00503295 2014-10-02
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Oncolytics Biotech
Phase 2 Completed
NCT00060944 2014-09-08
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00064220 2012-05-16
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Daiichi Sankyo
Phase 2 Completed